EirGenix, Inc.   Report issue

For profit Phase 1 Phase 3
Founded: Taipei Taiwan (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2016
NCT03180242
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

EirGenix, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

trastuzumab (herceptin) (2 trials)

Drugs in Phase 1 Trials (1)

pertuzumab (perjeta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2